With conventional corticosteroid treatment being effective in only 50-60% of patients, development of new treatment options is necessary to cover the unmet needs of the uveitis market. The market is currently dominated by corticosteroid treatment options and off-label immunosuppressive and biologic drugs. Although anterior uveitis patients constitute the major share of patients, except one, all the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. Drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile will have a significant impact on the uveitis market.
To Find more :
Visit : http://www.researchonglobalmarkets.com/opportunityanalyzer-uveitis-opportunity-analysis-and-forecasts-to-2017.html
Mail : support@researchonglobalmarkets.com
Blog: blog.researchonglobalmarkets.com
Call : +1 800 986 6819 / +91 22 4098 7600
